Malaysia Agrees to Accept U.S. FDA Approvals for Medical Devices

Recently, under the framework of the Agreement on Reciprocal Trade (ART) signed with the United States, Malaysia announced a new recognition mechanism for medical device regulation. According to arrangements reached between Malaysia’s Medical Device Authority (MDA) and U.S. regulatory authorities, FDA approval for certain medical devices in the United States may serve as an important basis for market approval in Malaysia.

I. Key Points

Malaysia and the United States have signed the ART, under which U.S.-manufactured medical devices approved by the U.S. FDA may be regarded as “sufficient evidence” that they meet Malaysia’s market access requirements.

However, the MDA has emphasized that FDA approval or clearance does not mean products can “automatically” enter the Malaysian market. Even U.S.-manufactured devices that have obtained FDA approval must still complete the registration process in Malaysia and undergo MDA review to ensure compliance with local regulatory, safety, and quality requirements.

Malaysia will grant U.S. conformity assessment bodies treatment no less favorable than that granted to its domestic bodies. It also agreed to facilitate the compliance of goods that do not require third-party conformity assessment under the U.S. regulatory framework with U.S. compliance procedures.

Malaysia will allow U.S.-origin goods that comply with applicable U.S. or international standards, U.S. technical regulations, or U.S. or international conformity assessment procedures to enter its market without additional conformity assessment requirements.

In addition, the ART requires Malaysia to recognize quality management system audits and certificates for U.S. manufacturers under the Medical Device Single Audit Program (MDSAP), and to adopt scientific and technical guidance documents developed by the International Medical Device Regulators Forum (IMDRF) in regulatory practice. This marks a further step in aligning Malaysia’s medical device regulatory system with international standards.

It is also worth noting that the MDA has clarified matters related to import duties on medical devices. Currently, U.S.-manufactured medical devices imported into Malaysia are generally subject to an import duty of approximately 19%. The ART does not remove this duty, but provides tariff exemptions for the following three categories of products:

1. Certain products containing antigens or antisera, such as some diagnostic reagents and contrast agents;

2. Medical lubricating gels;

3. Disinfectants specifically used for medical devices.

II. Significance

For U.S. medical device exporters, this means that FDA approval or U.S. market experience may help accelerate market access in Malaysia.

For Malaysia, the measure will help introduce more advanced medical devices backed by internationally recognized regulatory systems, potentially improving the technological level and accessibility of its medical device market.

At the same time, regulators have stressed that registration is still required. This serves as a reminder that FDA approval cannot be regarded as a substitute for the entire compliance process. Compliance, labeling, performance, safety monitoring, and post-market supervision must still meet Malaysia’s local laws and regulations.